Please Wait
Applying Filters...

Annual Sales of STRIBILD reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Genvoya

02 5Prezista/Prezcobix/Rezolsta/Symtuza

03 2Revenue share - Symtuza

04 8Stribild

05 3Symtuza

PharmaCompass

01

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

blank

02

Brand Name : Genvoya

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Genvoya

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 3,338

2019 Revenue in Millions : 3,931

Growth (%) : -15

blank

03

Brand Name : Stribild

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Stribild

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 196

2019 Revenue in Millions : 369

Growth (%) : -47

blank

04

Brand Name : Symtuza

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Symtuza

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 488

2019 Revenue in Millions : 379

Growth (%) : 29

blank

05

Brand Name : Genvoya

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Genvoya

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,879

2020 Revenue in Millions : 3,338

Growth (%) : -14

blank

06

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,083

2020 Revenue in Millions : 2,184

Growth (%) : -5

blank

07

Brand Name : Stribild

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Stribild

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 189

2020 Revenue in Millions : 196

Growth (%) : -4

blank

08

Brand Name : Symtuza

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Symtuza

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 531

2020 Revenue in Millions : 488

Growth (%) : 9

blank

09

Brand Name : Revenue share - Symtuza

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Revenue share - Symtuza

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 530

2021 Revenue in Millions : 531

Growth (%) : 0

blank

10

Brand Name : Stribild

Cobicistat

arrow
AAPS 2024
Not Confirmed

Brand Name : Stribild

arrow
AAPS 2024
Not Confirmed

Cobicistat

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 127

2021 Revenue in Millions : 189

Growth (%) : -33

blank